Compare ACAD & CAKE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACAD | CAKE |
|---|---|---|
| Founded | 1993 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.5B |
| IPO Year | 2000 | 1996 |
| Metric | ACAD | CAKE |
|---|---|---|
| Price | $24.83 | $85.00 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 16 |
| Target Price | $30.55 | ★ $60.31 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.92% |
| EPS Growth | ★ 69.12 | N/A |
| EPS | 0.02 | ★ 1.02 |
| Revenue | $726,437,000.00 | ★ $3,751,806,000.00 |
| Revenue This Year | $18.80 | $6.14 |
| Revenue Next Year | $11.70 | $6.65 |
| P/E Ratio | $1,241.50 | ★ $82.80 |
| Revenue Growth | ★ 40.45 | 4.75 |
| 52 Week Low | $19.69 | $43.07 |
| 52 Week High | $28.35 | $87.90 |
| Indicator | ACAD | CAKE |
|---|---|---|
| Relative Strength Index (RSI) | 51.72 | 64.39 |
| Support Level | $20.56 | $75.59 |
| Resistance Level | $25.36 | N/A |
| Average True Range (ATR) | 0.76 | 2.77 |
| MACD | -0.26 | -0.06 |
| Stochastic Oscillator | 23.84 | 73.48 |
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
The Cheesecake Factory Inc is a restaurant company that owns and operates multiple casual dining brands across the United States and Canada under brands that include The Cheesecake Factory, North Italia, Flower Child, and additional brands within its Fox Restaurant Concepts portfolio. The company's international presence, in the Middle East and Mexico, is through licensing agreements with third parties. The company also has a bakery division that produces cheesecakes and other baked products for sale in its restaurants, international licensees, and third-party bakery customers. The company has four operating business segments: The Cheesecake Factory restaurants, North Italia, Other FRC, and Other. The majority of the company's revenue comes from the Cheesecake Factory restaurants segment.